Hisamitsu begins Ph III trial fo HP-3150 for cancer pain

Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530) began a double-blind, placebo-controlled, Japanese Phase III trial of HP-3150 to treat pain in cancer patients. The company plans to submit the product for regulatory approval in 2020...